Dr Tomas Salmonson elected new chair of the Committee for Medicinal Products for Human Use (CHMP)
The Committee for Medicinal Products for Human Use (CHMP) has elected Tomas Salmonson as its new chair for a three-year mandate.
Dr Salmonson brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency (MPA). He has been a member of the CHMP for more than 12 years.
Since 2007, Dr Salmonson has been the elected vice-chair of the Committee. He has been acting chair of the CHMP since the departure of the previous chair Dr Eric Abadie in April 2012.
Accepting his election, Dr Salmonson said, “the CHMP has many challenges ahead and as a chair, I am committed to ensuring that we actively shape our own future.
"The regulation of medicines has become much more proactive over the past few years, and we must embrace the tools we have to shape drug development pre- and post-approval, for example by providing scientific advice to companies developing medicines and agreeing risk-management plans for new medicines coming to the market.”
The CHMP will elect a new vice-chair at its October 2012 meeting.